Kisspeptin
Also known as: Kisspeptin-54, Kisspeptin-10, Metastin, KISS1
Investigational Compound. This compound is currently in clinical development and has not received regulatory approval. No established commercial regimen exists. Consult a qualified clinician for the latest information on clinical trial availability.
Overview
Clinical Summary
Kisspeptin is a family of neuropeptides encoded by the KISS1 gene that play a fundamental role in reproductive endocrinology as the master regulator of the hypothalamic-pituitary-gonadal (HPG) axis. Synthetic kisspeptin (primarily kisspeptin-54 and kisspeptin-10) is under active investigation for reproductive medicine applications including IVF trigger, functional hypothalamic amenorrhea, and hypogonadism. It is also being studied for effects on sexual arousal and psychosexual function. Research is primarily led by groups at Imperial College London and Harvard.
Plain Language Summary
Kisspeptin is a natural hormone that acts as the 'master switch' for your reproductive system. It tells your brain to start the hormone cascade that leads to testosterone or estrogen production. Researchers are studying synthetic kisspeptin for fertility treatments and for boosting sexual desire. Early results are promising, especially for triggering egg maturation in IVF with less risk of a dangerous side effect called ovarian hyperstimulation. It is still investigational.
Mechanism of Action
Kisspeptin binds to the kisspeptin receptor (KISS1R, formerly GPR54) on GnRH neurons in the hypothalamus. This is the primary physiological trigger for GnRH pulse generation, making kisspeptin the upstream gatekeeper of the entire HPG axis. Kisspeptin-54 potently stimulates GnRH release, which in turn stimulates pituitary LH and FSH secretion. In IVF contexts, a single kisspeptin-54 dose can trigger oocyte maturation (LH surge) with a lower risk of ovarian hyperstimulation syndrome compared to hCG or GnRH agonist triggers. Kisspeptin also appears to modulate limbic brain circuits involved in sexual arousal, independent of its gonadotropin-releasing effects.
Evidence Summary
Clinical studies have demonstrated: (1) Kisspeptin-54 as an effective oocyte maturation trigger in IVF (Phase 2, Imperial College), with significantly reduced OHSS risk; (2) Restoration of pulsatile LH secretion in women with hypothalamic amenorrhea; (3) Stimulation of LH and testosterone in men with functional hypogonadism; (4) Enhancement of sexual brain processing and limbic activation on fMRI (Comninos et al., JCI 2017). Multiple Phase 2 trials are ongoing. The evidence is promising but not yet sufficient for regulatory approval.
Safety Profile
Kisspeptin has been well tolerated in clinical studies. No serious adverse events have been attributed to kisspeptin administration. The transient nature of its effects (short half-life of kisspeptin-54: approximately 28 minutes; kisspeptin-10: approximately 4 minutes) provides an inherent safety advantage. Potential for tachyphylaxis (reduced response with continuous administration) exists due to KISS1R desensitization. Long-term safety data are not available.
Contraindications
- Known hypersensitivity
- Sex hormone-dependent malignancies (theoretical, due to HPG axis activation)
- Pregnancy (stimulates gonadotropin release)
Adverse Events
- Injection site discomfort (mild)
- Warm sensation or flushing (transient)
- Mild nausea (rare)
- Generally very well tolerated in clinical studies
Interactions
- GnRH agonists/antagonists may interact with kisspeptin's HPG axis effects
- Sex hormone therapies may alter kisspeptin responsiveness
- No formal drug interaction studies
Regulatory Notes
Kisspeptin is an investigational agent. No regulatory approval has been granted by any authority. Active clinical research programs exist at Imperial College London and other academic centers. Commercial development may be pursued for IVF trigger and hypogonadism indications. Not available outside of clinical trials or research settings, though grey-market versions exist.
Monitoring Considerations
In research settings: LH, FSH, estradiol or testosterone levels to assess HPG axis response. In IVF: standard follicular monitoring. For sexual function studies: psychometric and neuroimaging assessments. Monitor for signs of OHSS if used as IVF trigger.
These are general considerations for clinical awareness and do not constitute prescriptive monitoring recommendations for any individual patient.
Stability and Handling Notes
Kisspeptin-54 has a short plasma half-life (approximately 28 minutes). Investigational formulations are typically lyophilized and reconstituted immediately before use. Stability data are limited to clinical trial protocols.
References
- 1RCT
Kisspeptin-54 as a Trigger for Oocyte Maturation in Women Undergoing IVF
Abbara A, Clarke SA, Islam R, et al. (2020). Journal of Clinical Investigation
Key findings: Kisspeptin-54 effectively triggered oocyte maturation in IVF with significantly reduced OHSS incidence compared to hCG trigger.
Limitations: Phase 2. Single-center. Moderate sample size.
View source - 2RCT
Kisspeptin Administration Enhances Brain Responses to Sexual and Emotional Images
Comninos AN, Wall MB, Demetriou L, et al. (2017). Journal of Clinical Investigation
Key findings: Kisspeptin increased limbic brain activation to sexual and romantic stimuli on fMRI, suggesting a role in psychosexual processing beyond gonadotropin release.
Limitations: Small sample (n=29 men). Acute administration only.
View source - 3review
Kisspeptin: A Multifunctional Peptide System with a Role in Reproduction, Cancer, and the Cardiovascular System
Clarke SA, Dhillo WS. (2016). Hormone Molecular Biology and Clinical Investigation
Key findings: Comprehensive review of kisspeptin biology covering reproductive endocrinology, oncology, and cardiovascular roles.
Limitations: Narrative review.
Last reviewed: 2024-11-20 | Version: 1 | Status: Published
More in Sexual Health
PT-141 (Bremelanotide)
Bremelanotide · Vyleesi · PT-141
Bremelanotide (brand name Vyleesi) is an FDA-approved medication for low sexual desire in premenopausal women. It works on receptors in the brain that are involved in sexual arousal and desire. It is given as a self-injection before anticipated sexual activity. It was originally discovered during research into tanning peptides (melanotan) when researchers noticed it increased sexual arousal as a side effect.
Gonadorelin
GnRH · LHRH · Factrel · Lutrepulse · Gonadotropin-Releasing Hormone
Gonadorelin is a synthetic version of the natural hormone (GnRH) that tells your pituitary gland to produce LH and FSH, which in turn stimulate testosterone production and sperm development. It is FDA-approved for testing pituitary function. Many men's health clinics use it alongside testosterone therapy to keep the testes active and maintain fertility. It can also be used to restore fertility in people with certain hormonal conditions.
Melanotan II
MT-II · MT-2 · Melanotan 2
Melanotan II is a peptide that causes skin tanning without UV exposure and also increases sexual arousal. It works by activating melanocortin receptors throughout the body. While it is popular in the grey market for tanning and sexual enhancement, it has serious safety concerns. Common side effects include severe nausea and changes in blood pressure. More concerning, it can cause moles to darken or change, raising worries about melanoma risk. It is not approved for any use and a safer derivative (bremelanotide/Vyleesi) was developed for sexual dysfunction instead.
Want to discuss this compound with a qualified physician?
The Peptide Association has verified over 160 licensed providers specializing in peptide therapy, with telehealth options available in most states.
Find a Verified Provider